AUTHOR=Franco-Moreno Anabel , Acedo-Gutiérrez María Soledad , Casado-Suela Miguel Ángel , Labrador-San Martín Nicolás , de Carranza-López María , Ibáñez-Estéllez Fátima , Hernández-Blanco Clara , Jiménez-Torres José , Vallejo-Maroto Ignacio , Romero-Pareja Rodolfo , Peña-Lillo Gabriela , Escobar-Rodríguez Ismael , Torres-Macho Juan ,  EARLY-DEX COVID-19 Research Group , Escolano-Fernández Belén , Alfaro-Fernández Nuria , Balado-Rico Mateo , Romero-Paternina Ana Rocío , Piniella-Ruiz Esther , Alonso-Monge Ester , Notario-Leo Helena , Bibiano-Guillén Carlos , Antiqueira-Pérez Armando , Cabello-Clotet Noemí 

TITLE=Effect of early administration of dexamethasone in patients with COVID-19 pneumonia without acute hypoxemic respiratory failure and risk of development of acute respiratory distress syndrome: EARLY-DEX COVID-19 trial

JOURNAL=Frontiers in Medicine

VOLUME=Volume 11 - 2024

YEAR=2024

URL=https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1385833

DOI=10.3389/fmed.2024.1385833

ISSN=2296-858X

ABSTRACT=Nº of Additional File: 1 (4.7%), with four in the treatment group and two in the control group. There were no deaths during hospitalization or during follow-up. An intermediate analysis for futility showed some differences between the control and treatment groups (Z=0.0284).However, these findings were within the margins close to the region where the null hypothesis would not be rejected.: In patients with COVID-19 pneumonia without oxygen needs but at risk of progressing to severe disease, early dexamethasone administration did not lead to a decrease in ARDS development. tre Trial registration: ClinicalTrials.gov NCT04836780. Registered on 8 April 2021 as EARLY-DEX COVID-19.